Overview Dividends

(MED) MEDIFAST - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58470H1014

Meal Replacement, Shakes, Bars, Snacks, Supplements

MED EPS (Earnings per Share)

EPS Growth (3Y CAGR): -62.28%
EPS Trend (3Y Correlation): -85.5%

MED Revenue

Revenue Growth (3Y CAGR): -37.85%
Revenue Trend (3Y Correlation): -98.9%

Description: MED MEDIFAST

Medifast Inc. (NYSE:MED) is a US-based company operating in the Personal Care Products sub-industry, specifically focusing on weight management and health products. The companys financial performance is a key driver of its stock value.

Analyzing the Income Tax Expense on a yearly basis can provide insights into the companys tax obligations and their impact on net income. A thorough examination of this metric can help identify trends and potential areas for optimization.

Key Performance Indicators (KPIs) to monitor for Medifast Inc. include revenue growth, gross margin ratio, and operating expense as a percentage of revenue. These metrics can help assess the companys ability to maintain profitability and manage costs. Additionally, tracking the companys Return on Equity (RoE) of 1.72% is crucial, as it indicates the return generated for shareholders.

The stocks valuation, with a Price-to-Earnings (P/E) ratio of 38.94, suggests that investors are willing to pay a premium for the companys earnings. This could be due to expected future growth or the companys position in the market. The absence of a Forward P/E ratio makes it challenging to assess the markets expectations for future earnings.

Economic drivers influencing Medifast Inc.s performance include consumer trends in health and wellness, competition in the weight management market, and overall economic conditions affecting consumer spending. The companys market capitalization of $141.24M USD indicates its size and potential for growth or vulnerability to market fluctuations.

MED Stock Overview

Market Cap in USD	145m
Sub-Industry	Personal Care Products
IPO / Inception	1993-12-31

MED Stock Ratings

Growth Rating	-82.6%
Fundamental	32.1%
Dividend Rating	20.0%
Return 12m vs S&P 500	-35.5%
Analyst Rating	3.0 of 5

MED Dividends

Currently no dividends paid

MED Growth Ratios

Growth Correlation 3m	12.4%
Growth Correlation 12m	-80.8%
Growth Correlation 5y	-94.7%
CAGR 5y	-37.12%
CAGR/Max DD 5y	-0.39
Sharpe Ratio 12m	-1.73
Alpha	-31.85
Beta	0.169
Volatility	45.09%
Current Volume	118.9k
Average Volume 20d	176.3k
Stop Loss	13.4 (-4.5%)
Signal	-0.56

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (3.64m TTM) > 0 and > 6% of Revenue (6% = 28.8m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -12.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 33.36% (prev 19.36%; Δ 13.99pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.02 (>3.0%) and CFO 4.15m > Net Income 3.64m (YES >=105%, WARN >=100%)

Net Debt (-88.6m) to EBITDA (14.2m) ratio: -6.25 <= 3.0 (WARN <= 3.5)

Current Ratio 4.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (11.1m) change vs 12m ago 1.12% (target <= -2.0% for YES)

Gross Margin 73.84% (prev 73.94%; Δ -0.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 170.7% (prev 262.4%; Δ -91.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.17 (EBITDA TTM 14.2m / Interest Expense TTM 2.94m) >= 6 (WARN >= 3)

Altman Z'' 9.59

(A) 0.60 = (Total Current Assets 206.4m - Total Current Liabilities 46.2m) / Total Assets 269.3m

(B) 0.66 = Retained Earnings (Balance) 178.5m / Total Assets 269.3m

(D) 3.35 = Book Value of Equity 178.7m / Total Liabilities 53.3m

Total Rating: 9.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.10

1. Piotroski 1.50pt = -3.50

2. FCF Yield data missing

3. FCF Margin 3.54% = 0.89

4. Debt/Equity 0.06 = 2.50

5. Debt/Ebitda 0.92 = 1.87

6. ROIC - WACC -6.17% = -7.72

7. RoE 1.72% = 0.14

8. Rev. Trend -98.94% = -4.95

9. Rev. CAGR -37.85% = -2.50

10. EPS Trend -85.52% = -2.14

11. EPS CAGR -62.28% = -2.50

What is the price of MED shares?

As of August 31, 2025, the stock is trading at USD 14.03 with a total of 118,900 shares traded.
Over the past week, the price has changed by -1.82%, over one month by -2.03%, over three months by +0.65% and over the past year by -24.57%.

Is MEDIFAST a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, MEDIFAST (NYSE:MED) is currently (August 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.10 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MED is around 8.73 USD . This means that MED is currently overvalued and has a potential downside of -37.78%.

Is MED a buy, sell or hold?

MEDIFAST has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold MED.

Strong Buy: 0
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MED price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	15	6.9%
Analysts Target Price	15	6.9%
ValueRay Target Price	9.5	-32%

Last update: 2025-08-18 02:03

MED Fundamental Data Overview

Market Cap USD = 145.0m (145.0m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 162.7m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 39.9697
P/S = 0.3017
P/B = 0.6712
P/EG = 1.95
Beta = 0.821
Revenue TTM = 480.4m USD
EBIT TTM = 487.0k USD
EBITDA TTM = 14.2m USD
Long Term Debt = 7.14m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.92m USD (from shortTermDebt, last quarter)
Debt = 13.1m USD (Calculated: Short Term 5.92m + Long Term 7.14m)
Net Debt = -88.6m USD (from netDebt column, last quarter)
Enterprise Value = -4.63m USD (145.0m + Debt 13.1m - CCE 162.7m)
Interest Coverage Ratio = 0.17 (Ebit TTM 487.0k / Interest Expense TTM 2.94m)
FCF Yield = -367.5% (FCF TTM 17.0m / Enterprise Value -4.63m)
FCF Margin = 3.54% (FCF TTM 17.0m / Revenue TTM 480.4m)
Net Margin = 0.76% (Net Income TTM 3.64m / Revenue TTM 480.4m)
Gross Margin = 73.84% ((Revenue TTM 480.4m - Cost of Revenue TTM 125.7m) / Revenue TTM)
Tobins Q-Ratio = -0.03 (set to none) (Enterprise Value -4.63m / Book Value Of Equity 178.7m)
Interest Expense / Debt = 4.59% (Interest Expense 600.0k / Debt 13.1m)
Taxrate = 44.78% (from yearly Income Tax Expense: 1.70m / 3.79m)
NOPAT = 268.9k (EBIT 487.0k * (1 - 44.78%))
Current Ratio = 4.47 (Total Current Assets 206.4m / Total Current Liabilities 46.2m)
Debt / Equity = 0.06 (Debt 13.1m / last Quarter total Stockholder Equity 216.0m)
Debt / EBITDA = 0.92 (Net Debt -88.6m / EBITDA 14.2m)
Debt / FCF = 0.77 (Debt 13.1m / FCF TTM 17.0m)
Total Stockholder Equity = 211.1m (last 4 quarters mean)
RoA = 1.35% (Net Income 3.64m, Total Assets 269.3m )
RoE = 1.72% (Net Income TTM 3.64m / Total Stockholder Equity 211.1m)
RoCE = 0.22% (Ebit 487.0k / (Equity 211.1m + L.T.Debt 7.14m))
RoIC = 0.13% (NOPAT 268.9k / Invested Capital 211.1m)
WACC = 6.30% (E(145.0m)/V(158.0m) * Re(6.64%)) + (D(13.1m)/V(158.0m) * Rd(4.59%) * (1-Tc(0.45)))
Shares Correlation 5-Years: -30.0 | Cagr: -1.57%
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.75% ; FCFE base≈32.0m ; Y1≈21.3m ; Y5≈9.98m
Fair Price DCF = 17.77 (DCF Value 195.3m / Shares Outstanding 11.0m; 5y FCF grow -39.06% → 3.0% )
Revenue Correlation: -98.94 | Revenue CAGR: -37.85%
Rev Growth-of-Growth: 7.69
EPS Correlation: -85.52 | EPS CAGR: -62.28%
EPS Growth-of-Growth: 61.02

Additional Sources for MED Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle